A 200-Mile Run for Multiple Myeloma

Blenrep improves durability and provides meaningful response rates to patients with relapsed/refractory multiple myeloma, researchers found.

In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.

On this episode of the “Cancer Horizons” podcast, a woman with multiple myeloma shares how she made the best of her cancer treatment process by channeling her emotions through fashion expression.

As majority leader Steve Scalise announces his new cancer diagnosis and author Ibram X. Kendi reveals that he is cancer free, this is what’s happening in the oncology space this week.

Elrexfio has been shown to provide patients with relapsed/refractory multiple myeloma who previously received four or more lines of therapy with a response that may last at least 15 months, an expert explained.